In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.
In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).
Patients with resected Crohn’s disease (CD) who were treated with the gut-selective α4β7-integrin inhibitor vedolizumab were less likely to have endoscopic signs of recurrence compared with placebo in the Reprevio study presented at DDW 2023.
The novel potassium-competitive acid blocker fexuprazan shows comparable safety and efficacy to the proton pump inhibitor esomeprazole in the treatment of Chinese patients with erosive esophagitis, as shown in the results of a phase III study presented at DDW 2023.
The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.
Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.
Digital gut-directed hypnotherapy (GDH) programme reduces abdominal pain in adults with irritable bowel syndrome (IBS) compared with digital muscle relaxation (MR), according to a study presented at DDW 2023.
More severe faecal incontinence symptoms appear to burden tobacco smokers, reveals a recent study presented at DDW 2023. Tobacco use is also associated with weaker anal sphincter tone and increased rectal hypersensitivity on high-resolution anorectal manometry (HRAM).
Induction therapy with guselkumab, an interleukin-23 p19 subunit antagonist, results in clinical and symptomatic remission, as well as other endoscopic improvements in patients with moderate-to-severe active ulcerative colitis (UC), according to the QUASAR study presented at DDW 2023.